Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].

Oreja-Guevara C.

Rev Neurol. 2012 Oct 1;55(7):421-30. Review. Spanish.

2.

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

Russo EB.

Neurology. 2003 Feb 25;60(4):729-30; author reply 729-30. No abstract available.

PMID:
12601130
3.

Sativex for the management of multiple sclerosis symptoms.

Perras C.

Issues Emerg Health Technol. 2005 Sep;(72):1-4.

PMID:
16317825
4.
5.

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.

Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group.

Eur J Neurol. 2007 Mar;14(3):290-6.

PMID:
17355549
6.

Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.

Giacoppo S, Bramanti P, Mazzon E.

Mult Scler Relat Disord. 2017 Oct;17:22-31. doi: 10.1016/j.msard.2017.06.015. Epub 2017 Jun 27. Review.

PMID:
29055461
7.

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.

Syed YY, McKeage K, Scott LJ.

Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Review.

PMID:
24671907
8.

[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].

Bazinski H, Jensen HB, Stenager E.

Ugeskr Laeger. 2015 May 11;177(20):956-60. Review. Danish.

PMID:
26535431
9.

Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?

Metz L, Page S.

Lancet. 2003 Nov 8;362(9395):1513. No abstract available.

PMID:
14615102
10.

[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].

Basinski H, Jensen HB, Stenager E.

Ugeskr Laeger. 2014 Mar 17;176(12A). pii: V09130552. Review. Danish.

PMID:
25350886
11.

Cannabis and cannabinoids.

[No authors listed]

Med Lett Drugs Ther. 2016 Aug 1;58(1500):97-8. No abstract available.

PMID:
27466748
13.

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.

Oreja-Guevara C.

Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. doi: 10.1586/ern.12.11. Review.

PMID:
22509985
14.

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

Sastre-Garriga J, Vila C, Clissold S, Montalban X.

Expert Rev Neurother. 2011 May;11(5):627-37. doi: 10.1586/ern.11.47. Epub 2011 Apr 1. Review.

PMID:
21456949
15.

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.

Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ.

Mult Scler. 2004 Aug;10(4):425-33.

PMID:
15327041
16.

Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.

Haupts M, Vila C, Jonas A, Witte K, Álvarez-Ossorio L.

Eur Neurol. 2016;75(5-6):236-43. doi: 10.1159/000445943. Epub 2016 May 10.

PMID:
27160412
17.

Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.

Lorente Fernández L, Monte Boquet E, Pérez-Miralles F, Gil Gómez I, Escutia Roig M, Boscá Blasco I, Poveda Andrés JL, Casanova-Estruch B.

Neurologia. 2014 Jun;29(5):257-60. doi: 10.1016/j.nrl.2013.06.014. Epub 2013 Sep 10. English, Spanish.

18.
20.

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.

Serpell MG, Notcutt W, Collin C.

J Neurol. 2013 Jan;260(1):285-95. doi: 10.1007/s00415-012-6634-z. Epub 2012 Aug 10.

PMID:
22878432

Supplemental Content

Support Center